Synopsis
Synopsis
0
CEP/COS
0
KDMF
0
VMF
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Bs 100 141
2. Bs-100-141
3. Bs100141
4. Estulic
5. Guanfacine
6. Guanfacine Monohydrochloride
7. Hydrochloride, Guanfacine
8. Lon798
9. Monohydrochloride, Guanfacine
10. Tenex
1. 29110-48-3
2. Guanfacine Hcl
3. Tenex
4. Intuniv
5. Guanfacine (hydrochloride)
6. N-carbamimidoyl-2-(2,6-dichlorophenyl)acetamide Hydrochloride
7. Estulic
8. Bs 100-141
9. 29520-14-7
10. N-(aminoiminomethyl)-2,6-dichlorobenzeneacetamide Hydrochloride
11. Spd503
12. N-amidino-2-(2,6-dichlorophenyl)acetamide Hydrochloride
13. N-amidino-2-(2,6-dichlorophenyl)acetamide Monohydrochloride
14. Guafacine Hydrochloride
15. Bs-100-141
16. Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-, Monohydrochloride
17. Spd 503
18. Mls000069745
19. Pml56a160o
20. Smr000058453
21. 29110-48-3 (hcl)
22. Dsstox_cid_25157
23. Dsstox_rid_80708
24. Dsstox_gsid_45157
25. Connexyn
26. Lon 798
27. N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide;hydrochloride
28. Cas-29520-14-7
29. Guanfacinehcl
30. Tenex (tn)
31. Guanfacinehydrochloride
32. Sr-01000075893
33. Ncgc00015469-05
34. Einecs 249-443-3
35. N-(aminoiminomethyl)-2,6-dichlorophenylacetamide Monohydrochloride
36. Unii-pml56a160o
37. Spd-503
38. Prestwick_740
39. Guanfacine Hydrochloride (jan/usp)
40. Intuniv (tn)
41. Mfcd00798230
42. Guanfacine Hydrochloride [usan:usp:jan]
43. Opera_id_1928
44. N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide Hydrochloride
45. Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-, Hydrochloride (1:1)
46. G 1043
47. Schembl41681
48. Mls001077329
49. Mls002222252
50. [(2,6-dichlorophenyl)acetyl]guanidine Hydrochloride
51. Chebi:5559
52. Chembl1200494
53. Dtxsid2045157
54. Schembl15603414
55. Hms1569c19
56. Hms3747e15
57. Pharmakon1600-01505435
58. Bcp21710
59. N-(aminoiminomethyl)-2,6-dichloro-benzeneacetamide Hydrochloride
60. Tox21_110159
61. Tox21_500519
62. Guanfacine Hydrochloride [mi]
63. Nsc759121
64. S4693
65. Guanfacine Hydrochloride [jan]
66. Akos015966858
67. Akos030242245
68. Tox21_110159_1
69. Ccg-213439
70. Ccg-220339
71. Cs-1254
72. Guanfacine Hydrochloride [usan]
73. Lp00519
74. Guanfacine Hydrochloride [mart.]
75. Guanfacine Hydrochloride [vandf]
76. Guanfacine Hydrochloride [usp-rs]
77. Guanfacine Hydrochloride [who-dd]
78. Ncgc00015469-09
79. Ncgc00093914-01
80. Ncgc00093914-02
81. Ncgc00180965-01
82. Ncgc00261204-01
83. As-12253
84. Hy-17416
85. Guanfacine Hydrochloride, >=98% (hplc)
86. Bs100-141
87. Db-047525
88. Eu-0100519
89. Ft-0630546
90. Ft-0698181
91. G0414
92. Guanfacine Hydrochloride [orange Book]
93. D00606
94. Guanfacine Hydrochloride [usp Monograph]
95. T72238
96. A826918
97. J-017395
98. S-877503
99. Sr-01000075893-1
100. Sr-01000075893-3
101. Sr-01000075893-6
102. Q27286641
103. N-carbamimidoyl-2-(2,6-dichlorophenyl)-acetamide Hydrochloride
104. Guanfacine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
105. Guanfacine Hydrochloride, United States Pharmacopeia (usp) Reference Standard
106. N-[bis(azanyl)methylidene]-2-[2,6-bis(chloranyl)phenyl]ethanamide Hydrochloride
Molecular Weight | 282.5 g/mol |
---|---|
Molecular Formula | C9H10Cl3N3O |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 1 |
Rotatable Bond Count | 2 |
Exact Mass | 280.988945 g/mol |
Monoisotopic Mass | 280.988945 g/mol |
Topological Polar Surface Area | 81.5 Ų |
Heavy Atom Count | 16 |
Formal Charge | 0 |
Complexity | 256 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Guanfacine hydrochloride |
Drug Label | Tenex (guanfacine hydrochloride) is a centrally acting antihypertensive with 2-adrenoceptor agonist properties in tablet form for oral administration. The chemical name of Tenex (guanfacine hydrochloride) is N-amidino- 2-(2,6-dichlorophenyl) acetam... |
Active Ingredient | Guanfacine hydrochloride |
Dosage Form | Tablet, extended release; Tablet |
Route | oral; Oral |
Strength | eq 4mg base; eq 2mg base; 1mg; eq 1mg base; eq 3mg base; 4mg; 2mg; 3mg |
Market Status | Tentative Approval; Prescription |
Company | Twi Pharms; Epic Pharma; Teva Pharms Usa; Sandoz; Watson Labs; Actavis Elizabeth; Amneal Pharm; Mylan |
2 of 4 | |
---|---|
Drug Name | Tenex |
PubMed Health | Guanfacine (By mouth) |
Drug Classes | Antihypertensive, Cardiovascular Agent, Central Nervous System Agent |
Drug Label | Tenex (guanfacine hydrochloride) is a centrally acting antihypertensive with 2-adrenoceptor agonist properties in tablet form for oral administration. The chemical name of Tenex (guanfacine hydrochloride) is N-amidino- 2-(2,6-dichlorophenyl) acetam... |
Active Ingredient | Guanfacine hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 2mg base; eq 1mg base |
Market Status | Prescription |
Company | Promius Pharma |
3 of 4 | |
---|---|
Drug Name | Guanfacine hydrochloride |
Drug Label | Tenex (guanfacine hydrochloride) is a centrally acting antihypertensive with 2-adrenoceptor agonist properties in tablet form for oral administration. The chemical name of Tenex (guanfacine hydrochloride) is N-amidino- 2-(2,6-dichlorophenyl) acetam... |
Active Ingredient | Guanfacine hydrochloride |
Dosage Form | Tablet, extended release; Tablet |
Route | oral; Oral |
Strength | eq 4mg base; eq 2mg base; 1mg; eq 1mg base; eq 3mg base; 4mg; 2mg; 3mg |
Market Status | Tentative Approval; Prescription |
Company | Twi Pharms; Epic Pharma; Teva Pharms Usa; Sandoz; Watson Labs; Actavis Elizabeth; Amneal Pharm; Mylan |
4 of 4 | |
---|---|
Drug Name | Tenex |
PubMed Health | Guanfacine (By mouth) |
Drug Classes | Antihypertensive, Cardiovascular Agent, Central Nervous System Agent |
Drug Label | Tenex (guanfacine hydrochloride) is a centrally acting antihypertensive with 2-adrenoceptor agonist properties in tablet form for oral administration. The chemical name of Tenex (guanfacine hydrochloride) is N-amidino- 2-(2,6-dichlorophenyl) acetam... |
Active Ingredient | Guanfacine hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 2mg base; eq 1mg base |
Market Status | Prescription |
Company | Promius Pharma |
Intuniv is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.
Intuniv must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.
Adrenergic alpha-2 Receptor Agonists
Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Agonists.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
C02AC02
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Guanfacine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Guanfacine, including repackagers and relabelers. The FDA regulates Guanfacine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Guanfacine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Guanfacine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Guanfacine supplier is an individual or a company that provides Guanfacine active pharmaceutical ingredient (API) or Guanfacine finished formulations upon request. The Guanfacine suppliers may include Guanfacine API manufacturers, exporters, distributors and traders.
click here to find a list of Guanfacine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Guanfacine DMF (Drug Master File) is a document detailing the whole manufacturing process of Guanfacine active pharmaceutical ingredient (API) in detail. Different forms of Guanfacine DMFs exist exist since differing nations have different regulations, such as Guanfacine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Guanfacine DMF submitted to regulatory agencies in the US is known as a USDMF. Guanfacine USDMF includes data on Guanfacine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Guanfacine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Guanfacine suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Guanfacine Drug Master File in Japan (Guanfacine JDMF) empowers Guanfacine API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Guanfacine JDMF during the approval evaluation for pharmaceutical products. At the time of Guanfacine JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Guanfacine suppliers with JDMF on PharmaCompass.
A Guanfacine written confirmation (Guanfacine WC) is an official document issued by a regulatory agency to a Guanfacine manufacturer, verifying that the manufacturing facility of a Guanfacine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Guanfacine APIs or Guanfacine finished pharmaceutical products to another nation, regulatory agencies frequently require a Guanfacine WC (written confirmation) as part of the regulatory process.
click here to find a list of Guanfacine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Guanfacine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Guanfacine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Guanfacine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Guanfacine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Guanfacine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Guanfacine suppliers with NDC on PharmaCompass.
Guanfacine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Guanfacine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Guanfacine GMP manufacturer or Guanfacine GMP API supplier for your needs.
A Guanfacine CoA (Certificate of Analysis) is a formal document that attests to Guanfacine's compliance with Guanfacine specifications and serves as a tool for batch-level quality control.
Guanfacine CoA mostly includes findings from lab analyses of a specific batch. For each Guanfacine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Guanfacine may be tested according to a variety of international standards, such as European Pharmacopoeia (Guanfacine EP), Guanfacine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Guanfacine USP).
LOOKING FOR A SUPPLIER?